INS and Hypoglycemia: In this analysis, no significant difference was observed between BIF and insulin degludec regarding the risk of alert, clinically significant, or nocturnal hypoglycaemia, a finding likely attributable to BIF's peakless pharmacodynamic profile that may alleviate concerns shared by both patients and clinicians [13].